IgGenix, Inc., a pre-clinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, announced today that the United States Patent and Trademark Office (USPTO) has issued patent No. 11,613,569, which covers the generation of allergen-specific antibodies.
April 4, 2023
· 2 min read
